E. Al-ezzi

发表

A Phase 2 Trial of Afatinib in Patients with Solid Tumors that Harbor Genomic Aberrations in the HER family: The MOBILITY3 Basket Study

Lisa I. Wang, L. Siu, P. Bedard, 2022, Targeted Oncology.

Genomic characterization of non-schistosomiasis-related squamous cell carcinoma of the urinary bladder: A retrospective exploratory study

T. H. van der Kwast, A. Zlotta, A. Finelli, 2021, PloS one.

Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration‐resistant prostate cancer treated with Radium‐223

C. Catton, P. Warde, A. Zlotta, 2021, Cancer medicine.

Biomarkers of response to immune checkpoint inhibitors for metastatic castration resistant prostate cancer: looking for the needle in the haystack.

A. Hansen, E. Al-ezzi, H. Alqaisi, 2020, Annals of translational medicine.

Selinexor, a First in Class, Nuclear Export Inhibitor for the Treatment of Advanced Malignant Peripheral Nerve Sheath Tumor.

S. D'Angelo, M. Gounder, B. Vincenzi, 2021, The oncologist.

A phase 1b trial of selinexor, a first-in-class selective inhibitor of nuclear export (SINE), in combination with doxorubicin in patients with advanced soft tissue sarcomas (STS).

J. Lewin, E. Malone, Abha A. Gupta, 2021, European journal of cancer.

Clinical outcomes of non‐osteogenic, non‐Ewing soft‐tissue sarcoma of bone––experience of the Toronto Sarcoma Program

J. Wunder, A. Griffin, Abha A. Gupta, 2020, Cancer medicine.

The role of cytoreductive nephrectomy and systemic therapy in the management of tumour thrombus in patients with metastatic renal cell carcinoma

A. Hansen, P. Chung, Xuan Li, 2022, British Journal of Cancer.